Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy

References

• Viard J-P, Souberbielle J-C, Kirk O, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011;25(10):1305–1315.
   PubMed Web of Science ®Google Scholar
• Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52(3):396–405.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tin A, Brown TT, et al. Vitamin D deficiency and metabolism in HIV-infected and HIV-uninfected men in the Multicenter AIDS Cohort Study. AIDS Res Hum Retroviruses. 2017;33(3):261–270.
   Web of Science ®Google Scholar
• Sassi F, Tamone C, D’Amelio P. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients 2018;10(11):e1656.
   PubMed Web of Science ®Google Scholar
• Rosen CI. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248–254.
   PubMed Web of Science ®Google Scholar
• Hamdy Al-Said N, Abd El Ghaffar Mohamed N, Salam RF, Fawzy MW. Vitamin D as a risk factor for premature atherosclerosis in patients with type 2 diabetes. Ther Adv Endocrinol. 2015;6(6):249–257.
   Web of Science ®Google Scholar
• Chen RH, Jiang XZ, Jiang Q, et al. Correlations between serum levels of 25-hydroxyvitamin D and carotid atherosclerosis in patients with type 2 diabetes in Shangai. Ann Endocrinol (Paris). 2014;75(4):206–212.
   Web of Science ®Google Scholar
• Perez Fontan M, Borras Sans M, Bajo Rubio MA, et al. Low serum levels of vitamin D are associated with progression of subclinical atherosclerotic vascular disease in peritoneal dialysis patients: a prospective, multicenter study. Nephron 2017; 136:111–120.
   Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)]. Eur Heart J. 2012;33(13):1635–1701.
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29.
   PubMed Web of Science ®Google Scholar
• Nitsa A, Toutouza M, Machairas N, Mariolis A, Philippou A, Koutsilieris M. Vitamin D in cardiovascular disease. In Vivo. 2018;32(5):977–981.
   PubMed Web of Science ®Google Scholar
• Aydin E, Altin C, Özcan Söylev G, Tekinday MA, Ağildere M. Assessment of subclinical atherosclerosis in vitamin D deficiency. Ultrasound Q 2018;35(2):142–146.
   Web of Science ®Google Scholar
• Marquina C, Mousa A, Scragg R, de Courten B. Vitamin D and cardiometabolic disorders: a review of current evidence, genetic determinants and pathomechanisms. Obes Rev. 2019;20(2):262–277.
   PubMed Web of Science ®Google Scholar
• Kheiri B, Abdalla A, Osman M, Ahmed S, Hassan M, Bachuwa G. Vitamin D deficiency and risk of cardiovascular diseases: a narrative review. Clin Hypertens. 2018;24(1):9.
   PubMedGoogle Scholar
• Rai V, Agrawal DK. Role of vitamin D in cardiovascular diseases. Endocrinol Metab Clin North Am. 2017;46(4):1039–1059.
   PubMed Web of Science ®Google Scholar
• Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44.
   PubMed Web of Science ®Google Scholar
• Scragg R. The Vitamin D Assessment (ViDA) study—design and main findings. J Steroid Biochem Mol Biol 2019;198:105562.
   Google Scholar
• Chen FH, Liu T, Xu L, Zhang L, Zhou XB. Association of serum vitamin D level and carotid atherosclerosis: a systematic review and meta-analysis. J Ultrasound Med. 2018;37(6):1293–1303.
   Web of Science ®Google Scholar
• Lupoli R, Vaccaro A, Ambrosino P, Poggio P, Amato M, Di Minno MN. Impact of vitamin D deficiency on subclinical carotid atherosclerosis: a pooled analysis of cohort studies. J Clin Endocrinol Metab. 2017;102(7):2146–2153.
   Web of Science ®Google Scholar
• Choi AI, Lo JC, Mulligan K, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis. 2011;52(7):941–944.
   Web of Science ®Google Scholar
• Ross AC, Judd S, Kumari M, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther. 2011;16(4):555–563.
   PubMed Web of Science ®Google Scholar
• Lai H, Fishman EK, Gerstenblith G, et al. Vitamin D deficiency is associated with development of subclinical coronary artery disease in HIV-infected African American cocaine users with low Framingham-defined cardiovascular risk. Vasc Health Risk Manag. 2013;9:729–737.
   PubMedGoogle Scholar
• Huff H, Merchant AT, Lonn E, et al. Vitamin D and progression of carotid intima-media thickness in HIV-positive Canadians. HIV Med. 2018;19(2):143–151.
   Web of Science ®Google Scholar
• Shikuma CM, Seto T, Liang CY, et al. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses. 2012;28(8):793–797.
   PubMed Web of Science ®Google Scholar
• Portilla J, Moreno-Perez O, Serna-Candel C, et al. Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV. J Int AIDS Soc. 2014;17(1):18945.
   Google Scholar
• Manion M, Hullsiek KH, Wilson EM, et al. Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons. PLoS One. 2017;12(5):e0175517.
   Web of Science ®Google Scholar
• Legeai C, Vigouroux C, Souberbielle JC, et al. Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naïve HIV-infected parsons: the ANRS CO9 “COPANA” cohort study. PLoS One. 2013;8(9):e74868.
   Web of Science ®Google Scholar
• Hoffman RM, Lake JE, Wilhalme HM, Tseng CH, Currier JS. Vitamin D levels and markers of inflammation and metabolism in HIV-infected individuals on suppressive antiretroviral therapy. AIDS Res Hum Retroviruses. 2016;32(3):247–254.
   Web of Science ®Google Scholar
• Carbone F, Satta N, Burger F, et al. Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. Vascul Pharmacol. 2016;85:57–65.
   Web of Science ®Google Scholar